Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

被引：0
作者：
Lu, S. [1 ]
Cheng, Y. [2 ]
Huang, D. [3 ]
Sun, Y. [4 ]
Wu, L. [5 ]
Zhou, C. [6 ]
Zhou, J. [7 ]
Guo, Y. [8 ]
Chen, L. [9 ]
Shao, J. [9 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Caner Ctr, Shanghai, Peoples R China
[2] Jilin Canc Hosp, Dept Thorac Oncol, Changchun, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Thorac Oncol, Tianjin, Peoples R China
[4] Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China
[5] Hunan Canc Hosp, Dept Thorac Med 2, Changsha, Peoples R China
[6] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis,Resp Med Dept, ffiliated Hosp 1,Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China
[7] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Resp Dis, Hangzhou, Peoples R China
[8] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Med Oncol, Shanghai, Peoples R China
[9] Eli Lilly & Co, Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Selpercatinib; RET fusion-positive NSCLC; China; ORR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA02.01
引用
收藏
页码：S888 / S889
页数：2
相关论文
共 50 条
  • [31] Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report
    Smesseim, Illaa
    van der Wel, Tijmen
    Badrising, Sushil K.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (12):
  • [32] Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
    Zhao, Lu
    Mei, Qingyun
    Yu, Yongchao
    Wang, Na
    Zhang, Dou
    Liao, Dongying
    Zuo, Jinhui
    Xie, Hongxia
    Jia, Yingjie
    Kong, Fanming
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Non-small-cell lung cancer: how to manage RET-positive disease
    Andrini, Elisa
    Mosca, Mirta
    Galvani, Linda
    Sperandi, Francesca
    Ricciuti, Biagio
    Metro, Giulio
    Lamberti, Giuseppe
    DRUGS IN CONTEXT, 2022, 11
  • [34] Effect of EGFR gene polymorphism on efficacy of chemotherapy combined with targeted therapy for non-small cell lung cancer in Chinese patients
    Wang, Youyu
    Xie, Shenglong
    He, Bin
    AMERICAN JOURNAL OF CANCER RESEARCH, 2019, 9 (03): : 619 - 627
  • [35] Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
    Zhou, Ning
    Li, Tong
    Liang, Maoli
    Ren, Fan
    Ni, Hong
    Liu, Wei
    Shi, Tao
    Xu, Dongbo
    Chen, Qiusong
    Yu, Haonan
    Song, Zuoqing
    Zu, Lingling
    Li, Shuo
    Xu, Song
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges
    Servetto, Alberto
    Esposito, Daniela
    Ferrara, Roberto
    Signorelli, Diego
    Belli, Stefania
    Napolitano, Fabiana
    Santaniello, Antonio
    Ciciola, Paola
    Formisano, Luigi
    Bianco, Roberto
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (06):
  • [37] Efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancers: results from the phase II LIBRETTO-321 study
    Zheng, Xiangqian
    Ji, Qinghai
    Sun, Yuping
    Ge, Minghua
    Zhang, Bin
    Cheng, Ying
    Lei, Shangtong
    Shi, Feng
    Guo, Ye
    Li, Linfa
    Chen, Lu
    Shao, Jingxin
    Zhang, Wanli
    Gao, Ming
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [38] Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review
    Setiwalidi, Kaidiriye
    Li, Yimeng
    Ma, Yuyan
    Hao, Zhanpeng
    Zhao, Yujia
    Zhang, Yuxin
    Liang, Xuan
    Tian, Tao
    Ruan, Zhiping
    Yao, Yu
    Fu, Xiao
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [39] Selpercatinib monotherapy in a Chinese patient with RET fusion/EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report
    Wu, Lin
    Cheng, Ying
    Huang, Dingzhi
    Sun, Yuping
    Zhou, Chengzhi
    Zhou, Jianying
    Guo, Ye
    Shao, Jingxin
    Zhang, Wanli
    Lu, Shun
    ANTI-CANCER DRUGS, 2023, 34 (09) : 1058 - 1064
  • [40] The efficacy and safety of targeted agents approved for advanced non-small cell lung cancer in China: a cross-sectional analysis
    Luo, Xingxian
    Du, Xin
    Lv, Xufeng
    Li, Lizong
    Huang, Lin
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2025, 55 : 97 - 97
12345